Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.

Background: Clinical and laboratory biomarkers in patients with advanced non-small-cell lung cancer (aNSCLC) receiving chemo-immunotherapy (CIT) are still poorly explored. Materials & methods: All consecutive aNSCLC patients who received at least one cycle of first-line CIT were enrolled. The impact of several clinical and laboratory biomarkers on outcomes was evaluated through Cox proportional hazard models. Results: Higher neutrophil-to-lymphocyte ratio was shown to be an independent prognostic biomarker of both worse progression-free survival and worse overall survival. The EPSILoN score was able to divide patients into three different prognostic groups, with a median overall survival of 73.2, 45.6 and 8.6 months for the favorable, intermediate and poor groups, respectively. Conclusion: The neutrophil-to-lymphocyte ratio and EPSILoN score were shown to have a prognostic value in aNSCLC patients treated with CIT.

[1]  M. Kriegsmann,et al.  Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer , 2021, ESMO open.

[2]  Jinming Yu,et al.  Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer , 2021, Cancer medicine.

[3]  R. Herbst,et al.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC , 2021, Nature Reviews Clinical Oncology.

[4]  S. Molina-Pinelo,et al.  Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab , 2021, Translational lung cancer research.

[5]  K. Kahnert,et al.  Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study , 2021, Scientific Reports.

[6]  C. Glass,et al.  Monocyte Regulation in Homeostasis and Malignancy. , 2021, Trends in immunology.

[7]  F. Ciardiello,et al.  Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. , 2020, Lung cancer.

[8]  M. Socinski,et al.  Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Nozomi Tani,et al.  Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer , 2020, Thoracic cancer.

[10]  A. Tafreshi,et al.  A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  R. Taboła,et al.  The usefulness of lactate dehydrogenase measurements in current oncological practice , 2020, Cellular & Molecular Biology Letters.

[12]  Wei-min Li,et al.  Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis , 2020, BMJ Open.

[13]  F. Trovò,et al.  Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system , 2020, Translational lung cancer research.

[14]  V. Longo,et al.  EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. , 2020, Clinical lung cancer.

[15]  J. Milanowski,et al.  CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. , 2020, European journal of cancer.

[16]  K. Egan,et al.  Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer , 2019, Scientific Reports.

[17]  V. Torri,et al.  EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort , 2019, Cancers.

[18]  D. Planchard,et al.  Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer , 2019, British Journal of Cancer.

[19]  L. Einhorn,et al.  Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Jingjing Liu,et al.  Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab , 2019, Journal of clinical laboratory analysis.

[21]  J. Blay,et al.  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? , 2019, Journal of Immunotherapy for Cancer.

[22]  N. Chaput,et al.  Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. , 2019, European journal of cancer.

[23]  G. Madonna,et al.  Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab , 2018, Journal of Immunotherapy for Cancer.

[24]  C. Carru,et al.  Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab , 2018, Cancer Immunology and Immunotherapy.

[25]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[26]  P. Shah,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis , 2017, Breast Cancer Research.

[27]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[28]  E. Felip,et al.  Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer , 2012, Clinical and Translational Oncology.

[29]  D. Galetta,et al.  Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.